Price$25.84+0.35 (+1.37%)
01:30 PM07:45 PM
News · 26 weeks58+100%
2026-03-012026-08-23
Mix2290d
- Insider10(45%)
- SEC Filings4(18%)
- Other4(18%)
- Earnings2(9%)
- Analyst2(9%)
Latest news
25 items- ANALYSTWells Fargo initiated coverage on Progyny with a new price targetWells Fargo initiated coverage of Progyny with a rating of Overweight and set a new price target of $37.00
- PRProgyny, Inc. to Present at the Canaccord Genuity Annual Growth ConferenceNEW YORK, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women’s health and family building solutions, today announced that its CEO Pete Anevski will present at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on Tuesday, August 11, 2026, at 3:30 p.m. ET. Live audiocasts and replays of the webcasted session will be available in the Events and Presentations section of Progyny’s investor relations website at http://investors.progyny.com. About Progyny Progyny (NASDAQ:PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world
- SECSEC Form 10-Q filed by Progyny Inc.10-Q - Progyny, Inc. (0001551306) (Filer)
- SECProgyny Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Progyny, Inc. (0001551306) (Filer)
- PRProgyny, Inc. Announces Second Quarter 2026 ResultsReports Record Quarterly Revenue, Gross Profit and Adjusted EBITDARobust Selling Season Activity Continues to Reflect Strong Demand for Women's Health, Family Building SolutionsValue Returned to Shareholders Through the Repurchase of Over 2 Million Shares Under Current Authorization NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) ("Progyny" or the "Company"), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended June 30, 2026 ("the second quarter of 2026"), as compared to the three-month period ended June 30, 2025 ("the second quarter of 2025" or "the prior year period"). "The st
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)
- ANALYSTProgyny downgraded by Barclays with a new price targetBarclays downgraded Progyny from Overweight to Equal Weight and set a new price target of $34.00
- PRProgyny, Inc. Announces Details for Its Second Quarter 2026 Results ReportNEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026. The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call. Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode. An
- INSIDERChief Operating Officer Cummings Melissa B covered exercise/tax liability with 1,193 shares and sold $70,910 worth of shares (2,244 units at $31.60) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 69,934 units (SEC Form 4) to satisfy withholding obligation4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERChief Product Officer Clapp Geoffrey covered exercise/tax liability with 819 shares, decreasing direct ownership by 1% to 59,828 units (SEC Form 4) to satisfy withholding obligation4 - Progyny, Inc. (0001551306) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Progyny Inc.SCHEDULE 13G/A - Progyny, Inc. (0001551306) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 1,421 shares and sold $64,184 worth of shares (2,517 units at $25.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 74,688 units (SEC Form 4) (tax withholding)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDEREVP, GC Swartz Allison covered exercise/tax liability with 1,015 shares and sold $45,022 worth of shares (1,798 units at $25.04) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 82,378 units (SEC Form 4) (for withholding tax)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Anevski Peter covered exercise/tax liability with 5,361 shares, decreasing direct ownership by 0.66% to 811,472 units (SEC Form 4) to satisfy tax liability4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 158 shares and sold $7,310 worth of shares (279 units at $26.20) as part of a pre-agreed trading plan, decreasing direct ownership by 0.55% to 78,626 units (SEC Form 4) (withholding tax)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERDirector Scott Cheryl exercised 14,667 shares at a strike of $13.00, covered exercise/tax liability with 7,228 shares and sold $196,278 worth of shares (7,439 units at $26.39) (SEC Form 4)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERChief Product Officer Clapp Geoffrey sold $39,137 worth of shares (1,530 units at $25.58), exercised 12,909 shares at a strike of $20.91 and covered exercise/tax liability with 11,379 shares (SEC Form 4) (for tax liability)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDEREVP, GC Swartz Allison covered exercise/tax liability with 1,352 shares and sold $61,053 worth of shares (2,398 units at $25.46) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 85,191 units (SEC Form 4) to cover withholding tax4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERDirector Gordon Kevin K sold $137,445 worth of shares (5,500 units at $24.99), disposed of 2,526 shares and acquired 2,526 shares, decreasing direct ownership by 54% to 6,792 units (SEC Form 4)4 - Progyny, Inc. (0001551306) (Issuer)
- PRNew Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare SystemNEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- A new survey from Progyny (NASDAQ:PGNY), a global leader in women's health and family building solutions, found that people navigating fertility, pregnancy, postpartum, and menopause care increasingly view personalized, human-led healthcare guidance as essential to managing stress and navigating a complex healthcare system. Among surveyed members, 71% said their healthcare journey added stress to their daily lives, with the top sources including the financial impact of healthcare and treatment, healthcare system complexity, and work/life balance challenges. Patients are not just managing healthcare decisions; they are also managing emotional stre
- SECSEC Form 144 filed by Progyny Inc.144 - Progyny, Inc. (0001551306) (Subject)
- SECProgyny Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Progyny, Inc. (0001551306) (Filer)
- INSIDERDirector Bierbower Elizabeth D was granted 5,660 shares (SEC Form 4)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERDirector Dean Lloyd H was granted 6,792 shares, increasing direct ownership by 34% to 26,519 units (SEC Form 4)4 - Progyny, Inc. (0001551306) (Issuer)
- INSIDERDirector Gordon Kevin K was granted 6,792 shares, increasing direct ownership by 85% to 14,818 units (SEC Form 4)4 - Progyny, Inc. (0001551306) (Issuer)
PGNY FAQ
7 questionsWhat does Progyny Inc. do?
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was...Where does PGNY stock trade?
Progyny Inc. (PGNY) is listed on NASDAQ.What sector and industry is PGNY in?
Progyny Inc. operates in the Health Care sector, Misc Health and Biotechnology Services industry.When did Progyny Inc. go public?
Progyny Inc. (PGNY) completed its IPO in 2019.What are analysts saying about PGNY?
Progyny Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $3700.00 price target on 2026-08-20. Recent price targets range from $2800.00 to $3700.00.What companies are similar to PGNY?
Notable peers in the same industry include FMS (Fresenius Medical Care AG), DVA (DaVita Inc.), SHC (Sotera Health Company), AGL (agilon health inc.), VMD (Viemed Healthcare Inc.). Compare PGNY side-by-side with any of them on Quantisnow.How can I track PGNY on Quantisnow?
Quantisnow aggregates Progyny Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PGNY to receive live email and push alerts on every new disclosure.